keyword
MENU ▼
Read by QxMD icon Read
search

leiomyosarcoma therapy

keyword
https://www.readbyqxmd.com/read/28649595/unusual-indolent-behavior-of-leiomyosarcoma-of-the-vagina-is-observation-a-viable-option
#1
Ayatallah M Khafagy, Lauren S Prescott, Anais Malpica, Shannon N Westin
•Primary leiomyosarcoma of the vagina is a rare disease.•We identified a case of unanticipated indolent behavior of vaginal leiomyosarcoma.•Observation or hormonal therapy may be viable option for select patients.
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28643747/leiomyosarcoma-of-scrotum-a-rare-in-field-second-malignancy-in-a-previously-irradiated-carcinoma-of-prostate-and-review-of-literature
#2
Chelakkot G Prameela, Rahul Ravind
BACKGROUND: Curative intent treatments for malignancies using radiation therapy while achieving longer disease-free survivals, may also lead to solid second malignancies, a dreaded late complication. Both in-field as well as out-field second malignancies are encountered and lead to diagnostic dilemma, and delay in treatment. MATERIALS AND METHODS: Details of a case of rare, in-field, radiation induced leiomyosarcoma, a rare soft tissue sarcoma, in a treated case of high risk carcinoma of prostate, who presented to our tertiary care centre was retrieved and analysed...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28641455/modulation-of-cisplatin-cytotoxic-activity-against-leiomyosarcoma-cells-by-epigallocatechin-3-gallate
#3
Irida Th Dhima, Dimitrios Peschos, Yannis V Simos, Maria I Gkiouli, Maria E Palatianou, Vasilios N Ragos, Vasiliki Kalfakakou, Angelos M Evangelou, Spyridon Ch Karkabounas
The aim of this study was to investigate the cytotoxic effect cisplatin in combination with epigallocatechin-3-gallate (EGCG) on leiomyosarcoma cells (LMS cells) in order to identify a less toxic but equally effective alternative. Assays for cell proliferation, colony formation efficiency, induction of apoptosis and cell cycle arrest were performed using the IC50 of cisplatin (8.6 μΜ) as a reference value and a concentration of EGCG (30 μΜ) that caused a non-significant reduction in cell proliferation...
June 23, 2017: Natural Product Research
https://www.readbyqxmd.com/read/28630682/overexpressed-prame-is-a-potential-immunotherapy-target-in-sarcoma-subtypes
#4
Jason Roszik, Wei-Lien Wang, John A Livingston, Christina L Roland, Vinod Ravi, Cassian Yee, Patrick Hwu, Andrew Futreal, Alexander J Lazar, Shreyaskumar R Patel, Anthony P Conley
BACKGROUND: PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies are currently in development for other cancers such as melanoma. METHODS: To map the landscape of PRAME expression in sarcoma, we used publicly available data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) projects and determined which sarcoma subtypes and subsets are associated with increased PRAME expression...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28625393/establishment-and-characterization-of-uterine-sarcoma-and-carcinosarcoma-patient-derived-xenograft-models
#5
Tine Cuppens, Jeroen Depreeuw, Daniela Annibali, Debby Thomas, Els Hermans, Ellen Gommé, Xuan Bich Trinh, David Debruyne, Philippe Moerman, Diether Lambrechts, Frédéric Amant
OBJECTIVE: Uterine sarcomas (US) and carcinosarcomas (CS) are rare, aggressive cancers. The lack of reliable preclinical models hampers the search for new treatment strategies and predictive biomarkers. To this end, we established and characterized US and CS patient-derived xenograft (PDX) models. METHODS: Tumor fragments of US and CS were subcutaneously implanted into immunocompromised mice. Engrafted xenograft and original tumors were compared by means of histology, immunohistochemistry, whole-genome low-coverage sequencing for copy number variations, and RNA sequencing...
June 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28621163/eribulin-in-advanced-liposarcoma-and-leiomyosarcoma
#6
Elisabetta Setola, Jonathan Noujaim, Charlotte Benson, Sant Chawla, Emanuela Palmerini, Robin L Jones
The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial...
June 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28618731/impact-of-adjuvant-treatment-on-oncologic-outcomes-in-patients-with-stage-i-leiomyosarcoma-of-the-uterus
#7
Gökhan Boyraz, Derman Başaran, M Coşkun Salman, Nejat Özgül, Kunter Yüce
BACKGROUND/AIM: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomyosarcoma (LMS). MATERIALS AND METHODS: Clinicopathological data of cases of stage I uterine LMS from 1998 to 2015 were retrieved from the computerized database of Hacettepe University Hospital. The Kaplan-Meier method was used to estimate survival and progression-free survival, and survival differences were analyzed by log-rank test. Cox regression analysis was performed to account for the potential influence of confounding factors...
June 12, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28591457/cutaneous-sarcomas
#8
Judith Kohlmeyer, Susanne Annette Steimle-Grauer, Rüdiger Hein
Cutaneous sarcomas comprise a heterogeneous group of mesenchymal spindle cell tumors of the dermis and subcutis, one of the best-known entities being dermatofibrosarcoma protuberans. Other sarcomas addressed in this review include atypical fibroxanthoma, cutaneous undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. With the exception of dermatofibrosarcoma protuberans, which has its peak incidence in middle-aged adults, cutaneous sarcomas usually occur in elderly individuals starting in the sixth or seventh decade of life...
June 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28591446/kutane-sarkome
#9
Judith Kohlmeyer, Susanne Annette Steimle-Grauer, Rüdiger Hein
Cutaneous sarcomas comprise a heterogeneous group of mesenchymal spindle cell tumors of the dermis and subcutis, one of the best-known entities being dermatofibrosarcoma protuberans. Other sarcomas addressed in this review include a typical fibroxanthoma, cutaneous undifferentiated pleomorphic sarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. With the exception of dermatofibrosarcoma protuberans, which has its peak incidence in middle-aged adults, cutaneous sarcomas usually occur in elderly individuals starting in the sixth or seventh decade of life...
June 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28580054/percutaneous-cholecystostomy-and-hydrodissection-in-radiofrequency-ablation-of-liver-subcapsular-leiomyosarcoma-metastasis-adjacent-to-the-gallbladder-protective-effect
#10
André Azevedo, Priscila Falsarella, Rafael Rocha, Antônio Rahal, Rodrigo Garcia
Uterine leiomyosarcoma is an uncommon pathology, predominantly found in aged population. Patients with metastatic disease have poor survival and therapy mainly consists of palliative systemic chemotherapy. However, more aggressive strategies such as radiofrequency ablation (RFA) may benefit patients with limited secondary disease. RFA is considered a simple and safe modality for treatment of hepatic lesions. The benefits related to RFA include low morbidity, short hospital stay and the possibility to repeat the procedure when necessary due to recurrences...
October 2016: Journal of Radiology Case Reports
https://www.readbyqxmd.com/read/28570276/macrophage-infiltration-and-genetic-landscape-of-undifferentiated-uterine-sarcomas
#11
Joanna Przybyl, Magdalena Kowalewska, Anna Quattrone, Barbara Dewaele, Vanessa Vanspauwen, Sushama Varma, Sujay Vennam, Aaron M Newman, Michal Swierniak, Elwira Bakuła-Zalewska, Janusz A Siedlecki, Mariusz Bidzinski, Jan Cools, Matt van de Rijn, Maria Debiec-Rychter
Endometrial stromal tumors include translocation-associated low- and high-grade endometrial stromal sarcomas (ESS) and highly malignant undifferentiated uterine sarcomas (UUS). UUS is considered a poorly defined group of aggressive tumors and is often seen as a diagnosis of exclusion after ESS and leiomyosarcoma (LMS) have been ruled out. We performed a comprehensive analysis of gene expression, copy number variation, point mutations, and immune cell infiltrates in the largest series to date of all major types of uterine sarcomas to shed light on the biology of UUS and to identify potential novel therapeutic targets...
June 2, 2017: JCI Insight
https://www.readbyqxmd.com/read/28541635/safety-of-ovarian-preservation-in-premenopausal-women-with-stage-i-uterine-sarcoma
#12
Dimitrios Nasioudis, Eloise Chapman-Davis, Melissa Frey, Kevin Holcomb
OBJECTIVE: To evaluate the oncologic safety of ovarian preservation (OP) in premenopausal women diagnosed with the International Federation of Gynecology and Obstetrics (FIGO) stage I uterine sarcoma. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was accessed and a cohort of women aged ≤50 diagnosed between 1988-2013 with a sarcoma limited to the uterus was drawn. Based on site-specific surgery codes, women who underwent hysterectomy with or without oophorectomy and did not receive radiation therapy were selected for further analysis...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28537682/elevated-ndc80-expression-is-associated-with-poor-prognosis-in-osteosarcoma-patients
#13
B Xu, D-P Wu, R-T Xie, L-G Liu, X-B Yan
OBJECTIVE: Osteosarcoma (OS) is a commonly diagnosed bone malignancy in children and adolescents. Nuclear division cycle 80 (NDC80) is a crucial regulator of the cell division cycle that has recently been identified as a novel oncoprotein in various solid tumors; however, its role in OS remains poorly understood. The aim of this study was to investigate correlations between NDC80 expression in OS patients and clinicopathological features and prognosis. PATIENTS AND METHODS: We began this study by determining NDC80 expression in sarcoma patients using the Oncomine Platform...
May 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28509136/primary-hepatic-leiomyosarcoma-in-a-patient-with-autosomal-dominant-polycystic-kidney-disease
#14
Takashi Iida, Tamaki Maeda, Yoshifumi Amari, Takatomi Yurugi, Yoshitane Tsukamoto, Fumitaka Nakajima
Primary hepatic leiomyosarcoma is an extremely rare tumor. The diagnosis is difficult, and its etiologic factors have not been clarified. A 63-year-old woman with numerous cysts in her kidneys and liver was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). Several members of her family also had ADPKD. She underwent treatment with tolvaptan to inhibit cyst growth and slow the decline in kidney function. Eight months after the start of the therapy, she was hospitalized with fatigue and fever of unknown origin...
May 2017: CEN Case Reports
https://www.readbyqxmd.com/read/28498251/undiagnosed-uterine-sarcomas-identified-during-surgery-for-presumed-leiomyoma-at-a-national-tertiary-hospital-in-thailand-a-10-year-review
#15
Irene Ruengkhachorn, Nisarat Phithakwatchara, Katika Nawapun, Suchanan Hanamornroongruang
OBJECTIVES: The aim of this study was to evaluate the rate, clinical characteristics, and survival outcomes of an undiagnosed uterine malignancy in patients who underwent surgical treatment for presumed leiomyomas. METHODS: Medical records of patients who underwent surgical treatment for presumed leiomyomas, from January 2004 to September 2013, were retrospectively reviewed, and the data were followed until September 2016. Demographic data, tumor characteristics, oncologic treatment, and response rate were analyzed by descriptive statistics...
June 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28484655/tumors-sharply-increased-after-ceasing-pazopanib-therapy-for-a-patient-with-advanced-uterine-leiomyosarcoma-experience-of-tumor-flare
#16
Terumi Tanigawa, Shintaro Morisaki, Hisanobu Fukuda, Shuichiro Yoshimura, Hisayoshi Nakajima, Kohei Kotera
Pazopanib has activity in patients with soft-tissue sarcoma. We report an advanced uterine leiomyosarcoma case that suddenly worsened after cessation of pazopanib therapy. A 47-year-old woman had a primary uterine leiomyosarcoma tumor and multiple lung metastases, which progressed during her initial treatment. In subsequent treatment with pazopanib for 3 months, the sum of her tumor diameters after cessation sharply increased for two weeks. Symptoms such as dyspnea suddenly worsened also. She died of the disease one month after cessation of pazopanib therapy...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28460536/review-of-past-and-present-clinical-cases-with-a-view-to-future-treatment-options
#17
Javier Martín-Broto, Peter Reichardt, Silvia Stacchiotti, Jean-Yves Blay
In the 10 years that have elapsed since trabectedin was first granted approval in Europe for treatment of advanced soft tissue sarcoma (STS), other cytotoxic agents and targeted therapies have been approved and numerous randomized controlled trials have been completed or are underway. As an academic exercise and positive proof of the advances in STS management that have occurred during the past decade, it is interesting to compare current and future treatment approaches. In this review, present and future treatment approaches are examined by case study for three STS subtypes: uterine leiomyosarcoma, abdominal dedifferentiated liposarcoma and malignant solitary fibrous tumor...
May 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28427752/spontaneously-arising-tumours-and-tumour-like-lesions-of-the-cervix-and-uterus-in-83-pet-guinea-pigs-cavia-porcellus
#18
C Laik-Schandelmaier, R Klopfleisch, S Schöniger, G Weiffenbach, M Staudacher, H Aupperle
Tumours and tumour-like lesions are rare findings in the genital system of guinea pigs. The aim of the present study was to characterize nodular lesions in the cervix and uterus of guinea pigs submitted for histopathological diagnosis. Samples from 83 pet animals were investigated. Cases included 64 surgically excised masses including complete uteri (n = 37), parts from uteri containing masses (n = 8), complete masses (n = 12) or samples from masses (n = 7) and 19 complete necropsy examinations. In 55 of the cases, only solitary changes were observed; in 28 cases two or more lesions were diagnosed...
April 17, 2017: Journal of Comparative Pathology
https://www.readbyqxmd.com/read/28427108/an-unusual-hypoechoic-solid-mass-in-the-pancreatic-head
#19
Valentin Blank, Katrin Schierle, Ulrich Hacker, Toni Herta, Vladan Vucinic, Albrecht Hoffmeister, Joachim Mössner, Boris Jansen-Winkeln, Volker Keim, Thomas Karlas
Solid pancreatic lesions found on imaging procedures are suspicious for malignancy and, therefore, demand immediate diagnostic evaluation and therapy. In the case of indeterminate histology, a primary resection should be considered in order to preserve the possibility of curative surgery, although rare entities may be initially disregarded. We present here the case of a 48-year-old female patient with a hypoechoic lesion of the pancreatic head, which was clearly delineated from the surrounding pancreatic tissue...
April 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/28424409/clinical-genomic-profiling-to-identify-actionable-alterations-for-investigational-therapies-in-patients-with-diverse-sarcomas
#20
Roman Groisberg, David S Hong, Vijaykumar Holla, Filip Janku, Sarina Piha-Paul, Vinod Ravi, Robert Benjamin, Shreyas Kumar Patel, Neeta Somaiah, Anthony Conley, Siraj M Ali, Alexa B Schrock, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Shiraj Sen, Cynthia Herzog, Funda Meric-Bernstam, Vivek Subbiah
BACKGROUND: There are currently no United States Food and Drug Administration approved molecularly matched therapies for sarcomas except gastrointestinal stromal tumors. Complicating this is the extreme diversity, heterogeneity, and rarity of these neoplasms. Few therapeutic options exist for relapsed and refractory sarcomas. In clinical practice many oncologists refer patients for genomic profiling hoping for guidance on treatment options after standard therapy. However, a systematic analysis of actionable mutations has yet to be completed...
June 13, 2017: Oncotarget
keyword
keyword
115503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"